Data from Pharmawand - Curated by Marshall Pearce - Date added 11 September 2017
Eli Lilly and Company presented key primary and secondary endpoint data at the 18th Congress of the International Headache Society (IHC for lasmiditan, an investigational, oral, first-in-class molecule for the acute treatment of migraine, which demonstrated statistically significant improvements compared to placebo in the Phase III SPARTAN study.
At two hours following the first dose, a greater percentage of patients treated with lasmiditan were migraine pain-free compared to placebo. These results were statistically significant across all three studied doses (50 mg, 100 mg and 200 mg). A statistically significantly greater percentage of patients were also free of their most bothersome symptom (MBS) compared with placebo at two hours. In this study, patients chose their MBS from nausea, sensitivity to sound or sensitivity to light. The majority of patients treated with lasmiditan also experienced relief from migraine pain—classified as mild or no pain—at two hours following the first dose (59 percent for 50 mg, 64.8 percent for 100 mg and 65 percent for 200 mg, p < 0.001 for all dosing groups).
These results were statistically significant compared to placebo (47.7 percent). In this study, fewer patients treated with lasmiditan took a second, rescue dose of treatment compared to placebo (41 percent for 50 mg; 32.7 percent for 100 mg; 26.4 percent for 200 mg and 49.8 percent for placebo).